Study of the effectiveness of Moxifloxacin in experimental colibacteriosis of laboratory animals
Abstract
Strains of Escherichia coli isolated from animals are commensal microorganisms, still some E. coli serotypes can cause pathology in animals. Accordingly new methods of treating colibacillosis are in demand. The goal of the present study was to determine the effectiveness of moxifloxacin for treatment of white mice, experimentally infected with E. coli. The drug was administered to laboratory animals intraperitoneally at a dose 20 mg per kg of body weight once a day and twice a day in the course of 1, 3, 5, 7 and 10 days. We found out that even a single administration of moxifloxacin makes it possible to achieve reliably better results, as compared to the control group. We also noted that the effectiveness of the administered drug was correspondent to the duration of treatment and the frequency of administration on days 1, 2 and 3 of the treatment. When treatment lasts one day moxifloxacin has low activity with single administration and it is active with two administrations per day. When treatment lasts 3 days the drug can be considered active with either method of administration, though the effectiveness of moxifloxacin and survivability of mice are reliably higher with 2 administrations per day. Maximum effectiveness was achieved when moxifloxacin was administered for 5, 7 and 10 days (active and highly active). Statistical analysis of the data obtained showed that frequency of administration on days 5 to 10 had little effect on the effectiveness of the drug. The…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.